Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 128 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Tirzepatide Clear all
Completed Phase 4 Interventional Results available

A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

NCT05564039
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
Cooper City, Florida • West Palm Beach, Florida • Skokie, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 7, 2026, 2:38 PM EDT
Recruiting No phase listed Observational

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

NCT07702461
View directory record Official record
Conditions
Obesity & Overweight, Diabetes (DM)
Interventions
Glucagon-Like Peptide-1 Agonist (GLP-1)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 7, 2026, 2:38 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

NCT06847399
View directory record Official record
Conditions
Obesity and Overweight, Binge Eating Disorder
Interventions
Tirzepatide, Lisdexamfetamine Dimesylate, Guided self-help cognitive behavioral therapy, Placebo (oral), Placebo (injection)
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

NCT03131687
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
tirzepatide, Dulaglutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Mobile, Alabama • Anaheim, California • Fresno, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 7, 2026, 2:38 PM EDT
Recruiting Not applicable Interventional

MAINTAIN (Mucosal AblatIoN Therapy After INcretins)

NCT06734312
View directory record Official record
Conditions
Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism, GLP-1, Ablation Techniques
Interventions
Gastric Fundal Mucosal Ablation (GFMA)
Device
Lead sponsor
Dr. Christopher McGowan
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 7, 2026, 2:38 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

NCT05912621
View directory record Official record
Conditions
Obesity, Overweight and Obesity, Overweight
Interventions
Tirzepatide
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 7, 2026, 2:38 PM EDT
Recruiting Phase 2 Interventional

Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

NCT06811324
View directory record Official record
Conditions
Obesity Prevention, Sarcopenia in Elderly, Cardiovascular Function, GLP - 1, Weight Loss
Interventions
Tirzepatide
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT04166773
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
47
States / cities
Birmingham, Alabama • Chandler, Arizona • Fresno, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 7, 2026, 2:38 PM EDT
Recruiting Phase 3 Interventional

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

NCT06439277
View directory record Official record
Conditions
Obesity, Weight Gain
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
14
States / cities
Los Angeles, California • Sacramento, California • Wilmington, Delaware + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 3 Interventional

A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

NCT06584916
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Pelham, Alabama • Santa Ana, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 1 Interventional Results available

A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity

NCT05696847
View directory record Official record
Conditions
Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 11 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia • Oklahoma City, Oklahoma • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 7, 2026, 2:38 PM EDT
Not yet recruiting Not applicable Interventional

High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)

NCT07700030
View directory record Official record
Conditions
Weight Loss
Interventions
High protein diet, Resistance Training (RT) Programs
Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
30 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 7, 2026, 2:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers

NCT06485089
View directory record Official record
Conditions
Obesity, Breast Cancer Risk
Interventions
tirzepatide
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
40 Years to 64 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Kansas City, Kansas • Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 3 Interventional

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

NCT06588296
View directory record Official record
Conditions
Psoriatic Arthritis, Obesity
Interventions
Ixekizumab, Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
81
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

NCT04657003
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, Obesity
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
938 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
43
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Park, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Sep 7, 2026, 2:38 PM EDT
Not yet recruiting Phase 3 Interventional

The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)

NCT07298915
View directory record Official record
Conditions
Obesity & Overweight
Interventions
Tirzepatide, Exercise
Drug · Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 7, 2026, 2:38 PM EDT
Recruiting Not applicable Interventional

Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation

NCT07387796
View directory record Official record
Conditions
Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide
Interventions
Discontinuation and Reinitiation of Tirzepatide
Other
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 4 Interventional

A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)

NCT06605703
View directory record Official record
Conditions
Obesity, Overweight
Interventions
WW Clinic, Bupropion-Naltrexone, Bupropion-Naltrexone-Metformin
Behavioral · Drug
Lead sponsor
WW International Inc
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

NCT04657016
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
45
States / cities
Huntington Park, California • Los Angeles, California • Montclair, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 7, 2026, 2:38 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

NCT05536804
View directory record Official record
Conditions
Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Northridge, California • Aurora, Colorado • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 7, 2026, 2:38 PM EDT
Recruiting Early Phase 1 Interventional

Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study

NCT06759701
View directory record Official record
Conditions
Diabetes, Prostate Cancer
Interventions
Tirzepatide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 1 Interventional Results available

A Study of Tirzepatide in Overweight and Very Overweight Participants

NCT04311411
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Tirzepatide, Placebo, Liraglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Indianapolis, Indiana • Baton Rouge, Louisiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 7, 2026, 2:38 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

NCT07218445
View directory record Official record
Conditions
Obesity, Menopause Hot Flashes
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
46 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 7, 2026, 2:38 PM EDT
Active, not recruiting Phase 3 Interventional

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06962280
View directory record Official record
Conditions
Type 1 Diabetes, Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Bonita, California • Escondido, California • Newport Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 7, 2026, 2:38 PM EDT